Celgene and Agios to target cancer metabolism in $250 million deal
This article was originally published in Scrip
Celgene and Agios Pharmaceuticals have agreed a $250 million deal to discover and develop therapies that target cancer metabolism.
You may also be interested in...
Celgene Corp. will pursue accelerated approval later this year for AG-221 (enasidenib), the lead drug candidate under its partnership with Agios Pharmaceuticals Inc., which may separately seek accelerated approval for its wholly-owned drug AG-120 in 2017, giving Agios's precision medicines a foothold in the oncology market while the collaborators work to expand the labeling for their drugs.
Agios Pharmaceuticals Inc. will get $200m to kick off a new partnership with longtime collaborator Celgene Corp. under a complex agreement to develop therapies that alter the metabolic state of immune cells to enhance the immune response to cancer.
AB Science has closed its IPO at just half of the value of its initial expectations. The gross proceeds of the French firm's offer were €27.5 million, compared with the €55.5 million it anticipated when it filed for the offering on 8 April. Of the total, the company secured $16.5 million from the sale of newly issued shares; the remaining €11 million went to selling shareholders.